← All trials
NCT07290699
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2026
- Primary completion
- Aug 30, 2027
- Completion date
- Aug 30, 2028
- First posted
- Dec 18, 2025
- Last posted
- Dec 18, 2025
- Enrollment
- 2442
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanchang UniversityLead sponsor
- Gannan Medical UniversityCollaborator
- Jiujiang First People's HospitalCollaborator
- The First People's Hospital of Changde CityCollaborator
- Xiangtan Central HospitalCollaborator
- Yueyang Central HospitalCollaborator
- ZhuZhou Central HospitalCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.